2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 624 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002855-15-DE
(EUCTR)
29/12/200402/12/2004A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis. Amyotrophic Lateral SclerosisProduct Code: TCH346
INN or Proposed INN: not established
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
480United Kingdom;Germany;Italy
2EUCTR2004-002855-15-GB
(EUCTR)
21/12/200404/05/2005A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis. Amyotrophic Lateral SclerosisProduct Code: TCH346
INN or Proposed INN: not established
INN or Proposed INN: not established
INN or Proposed INN: not established
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
480Germany;Italy;United Kingdom
3EUCTR2004-002855-15-IT
(EUCTR)
09/11/200408/01/2007A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg administered once daily in patients with Amyotrophic Lateral SclerosisA long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg administered once daily in patients with Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Code: TCH346
Product Code: TCH346
Product Code: TCH346
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
476United Kingdom;Germany;Italy
4NCT00230074
(ClinicalTrials.gov)
November 200428/9/2005A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)Amyotrophic Lateral SclerosisDrug: TCH346NovartisNULLCompleted21 Years80 YearsBoth350Phase 2United States
5NCT00072709
(ClinicalTrials.gov)
September 20037/11/2003Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: TCH346Novartis PharmaceuticalsNULLCompleted21 Years80 YearsBoth551Phase 2United States;Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom
6NCT00036413
(ClinicalTrials.gov)
January 20029/5/2002A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral SclerosisA 12-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Safety and Dose-ranging Study of Three Oral Doses (0.5 mg, 2.5 mg and 10 mg Once Daily) of TCH346 in Patients With Amyotrophic Lateral Sclerosis.Amyotrophic Lateral SclerosisDrug: TCH346Novartis PharmaceuticalsNULLCompleted40 Years75 YearsBoth44Phase 2United States